Anna Lloyd Email

Director Manufacturing . CEL-SCI Corporation

Current Roles

Employees:
18
Revenue:
$7.5M
About
CEL-SCI\'s story is one of vision, persistence, and survival in the face of overwhelming odds. Despite downturns in the biotech sector, lack of funding, and a lengthy clinical trial process associated with the development of its investigational therapy for advanced primary head and neck cancer, CEL-SCI is finally approaching the end game! Our lead investigational immunotherapy, Multikine® (Leukocyte Interleukin, Injection), has been tested in Phase I and II clinical trials, and is now enrolling patients for a global Phase III trial. Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.
CEL-SCI Corporation Address
8229 Boone Boulevard
Wolf Trap, VA
United States
CEL-SCI Corporation Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.